Skip to main content
Fig. 5 | Biomarker Research

Fig. 5

From: A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab

Fig. 5

High serum IL-1 levels may predict survival outcomes in a subset of cetuximab-resistant R/M HNSCC patients treated with cetuximab+ficlatuzumab. IL-1α (a) and IL-1β (b) levels were measured by ELISA in baseline serum samples from R/M cetuximab-resistant HNSCC patients scheduled for cetuximab in combination with ficlatuzumab. Progression free survival was compared for patients with “high” versus “low” serum levels of IL-1α (n = 8 vs n = 5 respectively) and IL-1β (n = 7 vs n = 6 respectively)

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us